Vibrational spectroscopic study of budesonide

The Raman spectrum of budesonide is reported for the first time, and molecular assignments are proposed on the basis of ab initio BLYP DFT calculations with a 6‐31 G* basis set and vibrational wavenumbers predicted on a quasi‐harmonic approximation. Comparison with previously published infrared data has explained several spectral features, and the relative band intensities in the CO and CC stretching regions are interpreted. The results from this study provide data that can be used for the preparative process monitoring of budesonide, an important steroidal pharmaceutical in various dosage forms, and its interaction with excipients and other components. Copyright © 2007 John Wiley & Sons, Ltd.     

Solubility of budesonide in {ethanol + water} mixtures from T = (293.2 to 313.2) K: Experimental measurement and mathematical modelling

The solubility of budesonide (BDS) in binary mixtures of ethanol and water at T = (293.2–313.2) K is determined and mathematically represented using two cosolvency models, i.e. Jouyban–Acree model and Jouyban–Acree–van’t Hoff model. The mean relative deviations for fitting the solubility data of BDS in binary mixtures of ethanol + water are 6.6% and 6.5%, respectively. Furthermore, the apparent thermodynamic properties, dissolution enthalpy, dissolution entropy, and Gibbs free energy change of dissolution process of BDS in all the mixed solvents were calculated according to van’t Hoff and Gibbs equations. Dissolution of BDS in these mixed solvents is an endothermic process.     

A full-scale tracing study of “ghost peaks” encountered in impurity analysis of budesonide based on experimental operation inspection-liquid chromatography/mass spectrometry fingerprint-mechanism based stress studies integrated strategy

Budesonide is an active pharmaceutical ingredient used in various dosage forms of finished products for the treatment of asthma. During the process of drug development, unbiased analysis of related substances is of utmost significance for both pharmaceutical research and quality control purposes. In this work, the official method documented in the United States Pharmacopoeia was selected to determine the related substances of budesonide considering the pros and cons of critical chromatographic parameters, compared to the European Pharmacopoeia. In doing so, several unpredictable interference peaks, namely “ghost peaks”, were observed occasionally during analysis. A strategy that integrated information derived from experimental operation inspection, liquid chromatography/mass spectrometry fingerprint analysis, and mechanism-based stress studies was then proposed for comprehensively and quickly exploring those non-degradable and degradable peaks. Some ghost peaks were found to originate from nylon syringe filter, illumination, and alkali borosilicate glass high-performance liquid chromatography vials. Besides, degradation pathways under alkaline conditions were also unraveled through liquid chromatography-mass spectrometry qualitative analysis. Overall, an optimization of the analytical methodology based on the United States Pharmacopoeia for its application in impurity analysis of budesonide and corresponding formulations was carried out with the design of experiments, by which “ghost peaks” could be suppressed or prevented. The results obtained herein are not only crucial to studies on budesonide's stability or degradation kinetics but also contribute to clarifying the impurity research of other drugs.     

Complexation of Budesonide in Cyclodextrins and Particle Aerodynamic Characterization of the Complex Solid Form for Dry Powder Inhalation

The purpose of this study is to evaluate the effect ofbudesonide-cyclodextrins (CDs) complex formation in thein-vitro aerodynamic properties of the dry powder producedfor pulmonary delivery. Phase-solubility studies were performedusing budesonide and -CD, DM--CD and HP--CD.The complex budesonide:DM--CD revealed the highest stabilityconstant (K_s = 3339.7 ± 4.76%; n = 3) and the solid powder was prepared by spray-drying.Complexation was evidenced by Differential Scanning Calorimetry (DSC). A physical mixture of budesonide and DM--CD was prepared for use as reference. The fine particle fraction and particle size distribution of both powders were assessed using Twin Stage Liquid Impinger (TSLI) and Aerosizer®LD, respectively. The content uniformity of the capsules filled (sd); (n) was 191.8 (± 2.74) g; (10) for the budesonide:DM--CD solid complex and 204.9 (± 9.35) g; (10) for the physical mixture. The emitted dose (rsd); (n) was 68.0% (± 26.1%); (5) of the nominal dose (solid complex) and 70.6% (± 12.6%); (5) (physical mixture). The fine particle fraction was 67.7% (± 18.9%); (5) of the emitted dose (solid complex) and 39.8% (± 16.9%); (5) (physical mixture). While no statistically significant difference was observed between the emitted dose means of both the solid complex and physical mixture, a statistically significant higher fine particle fraction mean was obtained for the solid complex. The results suggest that using a spray-dried CD complex powder for pulmonary drug delivery may increase the drug's respirable fraction and consequently its therapeutic efficacy.     

Determination and mathematical modelling of budesonide solubility in N-methyl-2-pyrrolidone + water mixtures from T = 293.2 to 313.2 K

The solubilities of budesonide (BDS) in binary aqueous mixtures of N-methyl-2-pyrrolidone at temperatures ranging from 293.2 to 313.2 K were determined and mathematically correlated by three cosolvency models, i.e. Jouyban–Acree model, Jouyban–Acree–van’t Hoff model and modified Wilson model. The solubilities were measured using the shake-flask method and the models wereused to fit the solubility data of BDS in the solvent mixtures. The obtained mean relative deviations (MRDs %) for cosolvency models trained using whole data points varied between 5.0% and 31.0%. Solubilities were also predicted by the generally trained version of the Jouyban–Acree model with the MRD of 37.0%. Furthermore, the apparent thermodynamic properties of dissolution process of BDS in all the mixed solvents were calculated according to van’t Hoff and Gibbs equations. Dissolution of BDS in these mixed solvents is an endothermic process.     

The in vitro Pulmonary Deposition of a Budesonide γ-Cyclodextrin Inclusion Complex

The interest in dry powder inhalers (DPIs) has recently increasedbecause the problems associated with the propellants used in pressurized metered-dose inhalers (PMDIs) will be avoided. Cyclodextrins (CDs) may be used as excipients in inhalation powders;e.g., in order to increase the solubility, stability and absorption of an inhaled drug. In thepresent study, the effect of complexation of budesonide with -CD on its pulmonary deposition wasstudied in vitro. In the presence of -CD, the aqueous solubility of budesonidefollowed B_S-type phase-solubility behaviour. A precipitationcomplexation method was used to prepare the solid budenoside/-CD complexes. The pulmonary in vitrodeposition of budenoside was evaluated after inhalation of plain budesonide and budenoside/-CDcomplexes (lactose carrier used in both formulations) by using the ``Andersen' cascadeimpactor. The novel Taifun® was used as the DPI. The respirable fractionsof the emitted budesonide dose (initially and after the storage in 40 °C, RH 75%) werecomparable for both plain budesonide and budesonide/-CD complexes. The present studyindicates that a drug/CD-complex can be used in inhalation powderswithout lowering the pulmonary deposition of the drug.     

直链淀粉-三[(S)-1-苯乙基氨基甲酸酯]手性固定相拆分布地奈德对映体及其制剂含量的测定

22R-布地奈德的药物活性比22S-布地奈德的强2~3倍,开发布地奈德对映体拆分和定量分析方法,可为其药物研发及质量控制提供重要依据。目前,主要以反相C₁₈固定相对布地奈德对映体进行拆分,而采用手性固定相对其进行拆分少有报道。通过考察固定相、流动相和柱温对布地奈德对映体拆分的影响,建立了基于直链淀粉-三[(S)-1-苯乙基氨基甲酸酯]手性固定相快速拆分和检测布地奈德对映体的高效液相色谱方法,其色谱条件如下:色谱柱为Chiralpak AS-RH色谱柱(150 mm×4.6 mm, 5.0 μm),流动相为乙腈-水(45∶55, v/v),柱温40 ℃,流速1.0 mL/min,二极管阵列检测器(DAD),检测波长246 nm,进样量10 μL。在该色谱条件下,布地奈德的两个对映体得到较好拆分,22R-布地奈德和22S-布地奈德的保留时间分别6.40 min和7.77 min,分离度为4.64; 22R-布地奈德和22S-布地奈德分别在各自范围内线性关系良好,相关系数(R²)均为0.9999,检出限分别为0.05 μg/mL和0.07 μg/mL,定量限分别为0.16 μg/mL和0.20 μg/mL; 4个添加水平的样品加标回收率为102.63%~104.17%,相对标准偏差(RSD)为0.08%~0.57%(n=6)。将该方法应用于1批次4个吸入用布地奈德混悬液实际样品进行检测,22R-布地奈德和22S-布地奈德的含量分别为283.15~284.63 μg/mL和259.86~261.51 μg/mL。该方法操作简便,分析时间短,重复性好,准确度高,可用于布地奈德对映体的拆分及其制剂的质量控制。     

沙丁胺醇联合布地奈德治疗支气管哮喘急性发作51例临床观察

目的观察临床应用沙丁胺醇联合布地奈德治疗小儿支气管哮喘急性发作治疗效果。方法选择支气管哮喘急性发作的小儿患者102例,将所有患儿随机分为观察组与对照组,各51例。对照组患儿在常规治疗的基础上单纯采用沙丁胺醇雾化吸入治疗,观察组患儿采用沙丁胺醇联合布地奈德雾化吸入治疗,观察两组的治疗效果。结果观察组的总有效率为96.08%,优于对照组的总有效率80.39%,由此可见此差异具有统计学意义(P0.05);不良反应发生率为5.8%,低于对照组9.8%,差异具有统计学意义(P0.05)。结论采用沙丁胺醇、布地奈德联合治疗支气管哮喘急性发作,具有较好的治疗效果,值得在临床上进一步推广应用。     

Identification and Quantification by NMR Spectroscopy of the 22R and 22S Epimers in Budesonide Pharmaceutical Forms

The authors developed four variants of the qNMR technique (¹H or ¹³C nucleus, DMSO-d6 or CDCl₃ solvent) for identification and quantification by NMR of 22R and 22S epimers in budesonide active pharmaceutical ingredient and budesonide drugs (sprays, capsules, tablets). The choice of the qNMR technique version depends on the drug excipients. The correlation of ¹H and ¹³C spectra signals to molecules of different budesonide epimers was carried out on the basis of a comprehensive analysis of experimental spectral NMR data (¹H-¹H gCOSY, ¹H-¹³C gHSQC, ¹H-¹³C gHMBC, ¹H-¹H ROESY). This technique makes it possible to identify budesonide epimers and determine their weight ratio directly, without constructing a calibration curve and using any standards. The results of measuring the 22S epimer content by qNMR are comparable with the results of measurements using the reference HPLC method.